Overview

CardinalStone Partners Limited is pleased to inform you of Fidson Healthcare PLC’s (“Fidson Healthcare” or the “Company”) Rights Issue of 600,000,000 Ordinary Shares at a fixed price of ₦35.00 per share (the “Rights Issue”). The Rights Issue is open to shareholders of the Company as at the Qualification Date of Wednesday, 12 November 2025. CardinalStone Partners Limited is acting as Joint Issuing House to the Rights Issue, opening today, 19 December 2025 and scheduled to close on Friday, 30 January 2026.

Fidson Healthcare Plc is Nigeria’s leading pharmaceutical manufacturing companies, engaged in the manufacturing, marketing, distribution, and sale of pharmaceutical and healthcare products across Nigeria and West Africa. The company currently manages over 350 registered pharmaceutical brands spanning various therapeutic areas..

The nine-month results for the period ended September 30, 2025, confirm this strength, revealing a significant 132% year-on-year surge in Profit After Tax (PAT) to reach N7.97 billion. This outstanding bottom-line growth was underpinned by a 56% increase in Revenue, which reached N93.08 billion, reflecting robust demand and expanded market reach. Furthermore, effective cost optimisation saw Operating Profit rise by an impressive 92% to N16.95 billion, demonstrating significant operational leverage and efficiency gains.

Key Financial Highlights